DK3774862T3 - Nye GLP-1-analoger - Google Patents
Nye GLP-1-analoger Download PDFInfo
- Publication number
- DK3774862T3 DK3774862T3 DK19724915.4T DK19724915T DK3774862T3 DK 3774862 T3 DK3774862 T3 DK 3774862T3 DK 19724915 T DK19724915 T DK 19724915T DK 3774862 T3 DK3774862 T3 DK 3774862T3
- Authority
- DK
- Denmark
- Prior art keywords
- analogs
- new glp
- glp
- new
- Prior art date
Links
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Transmission And Conversion Of Sensor Element Output (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201821013109 | 2018-04-05 | ||
| IN201821040468 | 2018-10-26 | ||
| IN201821040474 | 2018-10-26 | ||
| PCT/IB2019/052835 WO2019193576A1 (en) | 2018-04-05 | 2019-04-05 | Novel glp-1 analogues |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3774862T3 true DK3774862T3 (da) | 2022-09-05 |
Family
ID=66589592
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK19724915.4T DK3774862T3 (da) | 2018-04-05 | 2019-04-05 | Nye GLP-1-analoger |
| DK22177403.7T DK4122954T3 (da) | 2018-04-05 | 2019-04-05 | Novel GLP-1-analoger |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK22177403.7T DK4122954T3 (da) | 2018-04-05 | 2019-04-05 | Novel GLP-1-analoger |
Country Status (33)
| Country | Link |
|---|---|
| US (7) | US11447535B2 (da) |
| EP (3) | EP4364751A3 (da) |
| JP (2) | JP7250814B2 (da) |
| KR (2) | KR20250065720A (da) |
| CN (3) | CN117964735A (da) |
| AU (3) | AU2019247936C1 (da) |
| BR (1) | BR112020020419A2 (da) |
| CA (1) | CA3095988A1 (da) |
| CL (1) | CL2020002574A1 (da) |
| CO (1) | CO2020012425A2 (da) |
| DK (2) | DK3774862T3 (da) |
| EC (1) | ECSP20070185A (da) |
| ES (2) | ES2980707T3 (da) |
| FI (1) | FI4122954T3 (da) |
| HR (2) | HRP20240749T1 (da) |
| HU (2) | HUE060135T2 (da) |
| IL (1) | IL277483A (da) |
| JO (1) | JOP20200251A1 (da) |
| LT (2) | LT3774862T (da) |
| MX (2) | MX2020010505A (da) |
| MY (1) | MY202560A (da) |
| NZ (1) | NZ768446A (da) |
| PE (1) | PE20211417A1 (da) |
| PH (1) | PH12020551591A1 (da) |
| PL (2) | PL4122954T3 (da) |
| PT (2) | PT3774862T (da) |
| RS (2) | RS65639B1 (da) |
| SG (1) | SG11202009467YA (da) |
| SI (2) | SI4122954T1 (da) |
| SM (2) | SMT202400241T1 (da) |
| UA (1) | UA128210C2 (da) |
| WO (1) | WO2019193576A1 (da) |
| ZA (1) | ZA202306729B (da) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7250814B2 (ja) * | 2018-04-05 | 2023-04-03 | サン ファーマシューティカル インダストリーズ リミテッド | 新規ｇｌｐ－１類似体 |
| TWI829687B (zh) | 2018-05-07 | 2024-01-21 | 丹麥商諾佛 儂迪克股份有限公司 | 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物 |
| TW202216746A (zh) * | 2020-06-22 | 2022-05-01 | 印度商太陽製藥工業有限公司 | 長效型ｇｌｐ－１／ｇｉｐ雙重促效劑 |
| MX2023002906A (es) * | 2020-10-17 | 2023-04-05 | Sun Pharmaceutical Ind Ltd | Agonistas duales glp-1/gip. |
| CN114685646B (zh) * | 2020-12-31 | 2023-04-07 | 厦门赛诺邦格生物科技股份有限公司 | 一种多肽侧链类似物的制备方法及其应用 |
| IL304214B2 (en) | 2021-01-20 | 2025-01-01 | Viking Therapeutics Inc | Compositions and methods for treating metabolic and liver disorders |
| KR102873595B1 (ko) | 2021-09-15 | 2025-10-22 | 바이킹 테라퓨틱스 인코포레이티드 | 대사 및 간 장애의 치료를 위한 조성물 및 방법 |
| JP2024544920A (ja) | 2021-11-10 | 2024-12-05 | アイ２オー セラピューティクス，インク． | イオン液体組成物 |
| CN116514952B (zh) * | 2022-10-13 | 2024-02-02 | 江苏师范大学 | 一类glp-1类似物及其应用 |
| WO2024252366A1 (en) | 2023-06-09 | 2024-12-12 | Sun Pharmaceutical Industries Limited | Glp-1/gip dual, glp-1/gcg dual and glp-1/gip/gcg triple receptor agonists |
| WO2024261580A1 (en) | 2023-06-20 | 2024-12-26 | Sun Pharmaceutical Industries Limited | Glp-1 analog for use in the treatment of metabolic disorders |
| CN117756914B (zh) * | 2023-12-15 | 2024-09-03 | 瀚晖制药有限公司 | 依柯胰岛素的制备方法 |
| WO2025163615A1 (en) | 2024-01-31 | 2025-08-07 | Sun Pharmaceutical Industries Ltd. | High level production of glp1 analogues |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6849708B1 (en) | 1986-05-05 | 2005-02-01 | The General Hospital Corporation | Insulinotropic hormone and uses thereof |
| US6268343B1 (en) | 1996-08-30 | 2001-07-31 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
| ES2283025T3 (es) | 1996-08-30 | 2007-10-16 | Novo Nordisk A/S | Derivados de glp-1.1. |
| WO1999043708A1 (en) | 1998-02-27 | 1999-09-02 | Novo Nordisk A/S | Glp-1 derivatives of glp-1 and exendin with protracted profile of action |
| AU2610899A (en) | 1998-02-27 | 1999-09-15 | Novo Nordisk A/S | N-terminally modified glp-1 derivatives |
| AU2610699A (en) | 1998-02-27 | 1999-09-15 | Novo Nordisk A/S | Derivatives of glp-1 analogs |
| WO1999043705A1 (en) | 1998-02-27 | 1999-09-02 | Novo Nordisk A/S | N-terminally truncated glp-1 derivatives |
| FR2777283B1 (fr) | 1998-04-10 | 2000-11-24 | Adir | Nouveaux composes peptidiques analogues du glucagon-peptide- 1 (7-37), leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| DE69922043T2 (de) | 1998-12-07 | 2005-11-24 | Société de Conseils de Recherches et d'Applications Scientifiques S.A.S. | Glp-1 analoge |
| CA2412004C (en) | 2000-06-16 | 2010-12-21 | Eli Lilly And Company | Glucagon-like peptide-1 analogs |
| EP1355942B1 (en) | 2000-12-07 | 2008-08-27 | Eli Lilly And Company | Glp-1 fusion proteins |
| JP4282485B2 (ja) | 2002-01-08 | 2009-06-24 | イーライ リリー アンド カンパニー | 伸長グルカゴン様ペプチド−１アナログ |
| WO2004037859A1 (ja) | 2002-10-11 | 2004-05-06 | Sanwa Kagaku Kenkyusho Co., Ltd. | Glp-1誘導体及びその経粘膜吸収型製剤 |
| WO2004078777A2 (en) | 2003-03-04 | 2004-09-16 | Biorexis Pharmaceutical Corporation | Dipeptidyl-peptidase protected proteins |
| CA2525574C (en) | 2003-05-15 | 2015-06-30 | Trustees Of Tufts College | Stable analogs of peptide and polypeptide therapeutics |
| JP4949838B2 (ja) | 2003-09-19 | 2012-06-13 | ノヴォ ノルディスク アー／エス | 新規ｇｌｐ−１誘導体 |
| EP2210900A3 (en) | 2003-12-16 | 2010-08-11 | Ipsen Pharma | Analogues of GLP-1 |
| WO2006037810A2 (en) | 2004-10-07 | 2006-04-13 | Novo Nordisk A/S | Protracted glp-1 compounds |
| TWI372629B (en) * | 2005-03-18 | 2012-09-21 | Novo Nordisk As | Acylated glp-1 compounds |
| AU2006224537A1 (en) | 2005-03-18 | 2006-09-21 | Novo Nordisk A/S | Extended GLP-1 compounds |
| EP1883419A4 (en) | 2005-05-06 | 2010-08-04 | Bayer Pharmaceuticals Corp | GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS AND THEIR PHARMACOLOGICAL USES |
| AU2006287562B2 (en) | 2005-09-08 | 2012-05-10 | Trustees Of Tufts College | Stabilized GLP-1 analogs |
| EP2045265B1 (en) | 2005-09-22 | 2012-11-21 | Biocompatibles Uk Ltd. | GLP-1 (Glucagon-like peptide-1) fusion polypeptides with increased peptidase resistance |
| EP2190460B1 (en) | 2007-09-05 | 2014-12-17 | Novo Nordisk A/S | Peptides derivatized with a-b-c-d- and their therapeutical use |
| CA2702289A1 (en) | 2007-10-30 | 2009-05-07 | Indiana University Research And Technology Corporation | Compounds exhibiting glucagon antagonist and glp-1 agonist activity |
| HUE027229T2 (en) | 2009-12-16 | 2016-08-29 | Novo Nordisk As | Double acylated glp-1 derivatives |
| BR112012027545B1 (pt) | 2010-04-27 | 2020-09-24 | Betta Pharmaceuticals Co., Ltd. | Composto, composição farmacêutica, uso da composição farmacêutica e uso de um composto |
| WO2012016419A1 (zh) | 2010-08-06 | 2012-02-09 | 浙江贝达药业有限公司 | Glp-1衍生物及其应用 |
| ES2683372T3 (es) | 2010-11-09 | 2018-09-26 | Novo Nordisk A/S | Derivados de GLP-1 acilados con un conector nuevo |
| BR112013026195A2 (pt) | 2011-04-12 | 2016-11-29 | Novo Nordisk As | derivados de glp-1 duplamente acilados |
| WO2012150503A2 (en) | 2011-05-03 | 2012-11-08 | Zealand Pharma A/S | Glu-glp-1 dual agonist signaling-selective compounds |
| CN107266558A (zh) | 2011-09-06 | 2017-10-20 | 诺沃—诺迪斯克有限公司 | Glp‑1衍生物 |
| EP2578599A1 (en) | 2011-10-07 | 2013-04-10 | LanthioPep B.V. | Cyclic analogs of GLP-1 and GLP-1 related peptides |
| CN104411322B (zh) | 2012-05-08 | 2017-05-24 | 诺和诺德股份有限公司 | 双酰化glp‑1衍生物 |
| JP6250034B2 (ja) | 2012-05-08 | 2017-12-20 | ノヴォ ノルディスク アー／エス | 二重アシル化されたｇｌｐ−１誘導体 |
| CA2875743A1 (en) | 2012-06-14 | 2013-12-19 | Sanofi | Exendin-4 peptide analogues |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| TWI617574B (zh) | 2012-12-11 | 2018-03-11 | 梅迪繆思有限公司 | 用於治療肥胖之升糖素與ｇｌｐ－１共促效劑 |
| SG10201705097PA (en) | 2012-12-21 | 2017-07-28 | Sanofi Sa | Functionalized exendin-4 derivatives |
| JP6475233B2 (ja) | 2013-06-20 | 2019-02-27 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１誘導体及びその使用 |
| US9738697B2 (en) | 2013-06-23 | 2017-08-22 | Wisconsin Alumni Research Foundation | Alpha/beta-polypeptide analogs of glucagon-like peptide-1 |
| AR096789A1 (es) | 2013-07-04 | 2016-02-03 | Novo Nordisk As | Derivados de péptidos similares a glp-1 y usos de los mismos |
| CN105451776B (zh) | 2013-08-15 | 2020-04-17 | 诺和诺德股份有限公司 | Glp-1衍生物及其用途 |
| RS57632B1 (sr) * | 2013-10-17 | 2018-11-30 | Zealand Pharma As | Acilovani analozi glukagona |
| TW201609797A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重ｇｌｐ－１／升糖素受體促效劑 |
| MX2016007407A (es) | 2013-12-13 | 2016-12-12 | Medimmune Ltd | Peptidos resistentes a proteasa. |
| TW201609800A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 做為雙重ｇｌｐ－１／升糖素受體促效劑之艾塞那肽－４胜肽類似物 |
| JP6730278B2 (ja) | 2014-11-27 | 2020-07-29 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１誘導体及びその使用 |
| JP6691125B2 (ja) | 2014-12-17 | 2020-04-28 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１誘導体及びその使用 |
| TWI726889B (zh) | 2015-06-10 | 2021-05-11 | 英商梅迪繆思有限公司 | 蛋白酶抗性之脂化肽 |
| WO2017035432A1 (en) | 2015-08-26 | 2017-03-02 | Robert Doyle | Coagonists of glucagon-like peptide 1 receptor and neuropeptide y2 receptor |
| CN108699126B (zh) | 2016-03-03 | 2022-12-06 | 诺和诺德股份有限公司 | Glp-1衍生物及其用途 |
| JP2019525732A (ja) | 2016-06-09 | 2019-09-12 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | プロテアーゼ耐性一脂質付加ペプチド |
| ES2828526T3 (es) | 2016-11-07 | 2021-05-26 | Novo Nordisk As | Esteres activos DCHBS de compuestos PEG y sus usos |
| TW201833131A (zh) | 2016-12-02 | 2018-09-16 | 法商賽諾菲公司 | 作為胜肽類ｇｌｐ１／升糖素／ｇｉｐ受體促效劑之新化合物 |
| WO2018178796A1 (en) | 2017-03-27 | 2018-10-04 | Sun Pharmaceutical Industries Limited | Method for making kex1 protease sensitive polypeptides using yeast strain |
| PL3704143T3 (pl) | 2018-03-09 | 2024-04-15 | Fresenius Kabi Ipsum S.R.L. | Chemo-enzymatyczna synteza liraglutydu, semaglutydu i glp-1 |
| JP7250814B2 (ja) * | 2018-04-05 | 2023-04-03 | サン ファーマシューティカル インダストリーズ リミテッド | 新規ｇｌｐ－１類似体 |
-
2019
- 2019-04-05 JP JP2020553627A patent/JP7250814B2/ja active Active
- 2019-04-05 EP EP24161843.8A patent/EP4364751A3/en active Pending
- 2019-04-05 KR KR1020257013603A patent/KR20250065720A/ko active Pending
- 2019-04-05 SM SM20240241T patent/SMT202400241T1/it unknown
- 2019-04-05 AU AU2019247936A patent/AU2019247936C1/en active Active
- 2019-04-05 WO PCT/IB2019/052835 patent/WO2019193576A1/en not_active Ceased
- 2019-04-05 MX MX2020010505A patent/MX2020010505A/es unknown
- 2019-04-05 RS RS20240706A patent/RS65639B1/sr unknown
- 2019-04-05 PL PL22177403.7T patent/PL4122954T3/pl unknown
- 2019-04-05 RS RS20220814A patent/RS63523B1/sr unknown
- 2019-04-05 NZ NZ768446A patent/NZ768446A/en unknown
- 2019-04-05 ES ES22177403T patent/ES2980707T3/es active Active
- 2019-04-05 KR KR1020207031696A patent/KR102801994B1/ko active Active
- 2019-04-05 CA CA3095988A patent/CA3095988A1/en active Pending
- 2019-04-05 DK DK19724915.4T patent/DK3774862T3/da active
- 2019-04-05 PE PE2020001535A patent/PE20211417A1/es unknown
- 2019-04-05 HU HUE19724915A patent/HUE060135T2/hu unknown
- 2019-04-05 HR HRP20240749TT patent/HRP20240749T1/hr unknown
- 2019-04-05 LT LTEPPCT/IB2019/052835T patent/LT3774862T/lt unknown
- 2019-04-05 PT PT197249154T patent/PT3774862T/pt unknown
- 2019-04-05 BR BR112020020419-6A patent/BR112020020419A2/pt unknown
- 2019-04-05 SG SG11202009467YA patent/SG11202009467YA/en unknown
- 2019-04-05 MY MYPI2020004864A patent/MY202560A/en unknown
- 2019-04-05 LT LTEP22177403.7T patent/LT4122954T/lt unknown
- 2019-04-05 DK DK22177403.7T patent/DK4122954T3/da active
- 2019-04-05 SI SI201930764T patent/SI4122954T1/sl unknown
- 2019-04-05 EP EP19724915.4A patent/EP3774862B1/en active Active
- 2019-04-05 ES ES19724915T patent/ES2925678T3/es active Active
- 2019-04-05 HR HRP20221054TT patent/HRP20221054T1/hr unknown
- 2019-04-05 HU HUE22177403A patent/HUE067499T2/hu unknown
- 2019-04-05 PL PL19724915.4T patent/PL3774862T3/pl unknown
- 2019-04-05 FI FIEP22177403.7T patent/FI4122954T3/fi active
- 2019-04-05 US US16/376,190 patent/US11447535B2/en active Active
- 2019-04-05 CN CN202311777728.0A patent/CN117964735A/zh active Pending
- 2019-04-05 SI SI201930322T patent/SI3774862T1/sl unknown
- 2019-04-05 UA UAA202006178A patent/UA128210C2/uk unknown
- 2019-04-05 CN CN201980037166.1A patent/CN112236444B/zh active Active
- 2019-04-05 EP EP22177403.7A patent/EP4122954B1/en active Active
- 2019-04-05 CN CN202510743440.4A patent/CN120554480A/zh active Pending
- 2019-04-05 SM SM20220352T patent/SMT202200352T1/it unknown
- 2019-04-05 PT PT221774037T patent/PT4122954T/pt unknown
- 2019-04-05 JO JOP/2020/0251A patent/JOP20200251A1/ar unknown
-
2020
- 2020-08-04 US US16/985,207 patent/US11242373B2/en active Active
- 2020-09-21 IL IL277483A patent/IL277483A/en unknown
- 2020-09-29 PH PH12020551591A patent/PH12020551591A1/en unknown
- 2020-10-02 CO CONC2020/0012425A patent/CO2020012425A2/es unknown
- 2020-10-05 CL CL2020002574A patent/CL2020002574A1/es unknown
- 2020-10-05 MX MX2024007688A patent/MX2024007688A/es unknown
- 2020-11-05 EC ECSENADI202070185A patent/ECSP20070185A/es unknown
- 2020-12-28 US US17/134,982 patent/US11485766B2/en active Active
-
2022
- 2022-08-01 US US17/816,577 patent/US11873328B2/en active Active
- 2022-08-12 US US17/819,466 patent/US11866477B2/en active Active
-
2023
- 2023-03-22 JP JP2023045498A patent/JP2023078367A/ja active Pending
- 2023-06-01 AU AU2023203430A patent/AU2023203430B2/en active Active
- 2023-06-30 ZA ZA2023/06729A patent/ZA202306729B/en unknown
- 2023-11-21 US US18/515,712 patent/US12421289B2/en active Active
-
2024
- 2024-05-17 US US18/667,531 patent/US20240376175A1/en active Pending
-
2025
- 2025-10-02 AU AU2025242190A patent/AU2025242190A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3774862T3 (da) | Nye GLP-1-analoger | |
| IL280913A (en) | Novel methods | |
| DK3883936T3 (da) | Nye heterocykliske forbindelser | |
| LT3810602T (lt) | Junginiai | |
| EP3781156A4 (en) | SPIROCYCLIC COMPOUNDS | |
| DK3810587T3 (da) | Substituerede alkoxypyridinylindolsulfonamider | |
| MA52090A (fr) | Polythérapie | |
| EP3781060A4 (en) | CRYOPROBE | |
| IL282330A (en) | Therapeutic compounds | |
| EP3784463A4 (en) | Fluorosulfones | |
| EP3836173A4 (en) | REACTOR | |
| EP3746155A4 (en) | SYRINGE SET | |
| IL279620B1 (en) | Compounds | |
| IL280422A (en) | Bag on valve technology | |
| LT3867247T (lt) | Naujieji junginiai | |
| DK3445742T3 (da) | Krystallin tapentadolphosphat | |
| IL283673A (en) | Deuterated analogs of acetyl-leucine | |
| EP3849328C0 (en) | MICROEMULSIONS CONTAINING ANTIOXIDANTS | |
| EP3721129A4 (en) | CRYOSPHERE | |
| EP3487876A4 (en) | INSULIN ANALOGS | |
| EP3866808A4 (en) | NEW USES | |
| EP3836174A4 (en) | REACTOR | |
| DK3620208T3 (da) | Kanyle | |
| EP3773733A4 (en) | METALLO-LIOTHYRONINE | |
| DK3412667T3 (da) | Cokrystal |